Aptinyx Inc (OQ:APTX)

Business Focus: Biopharmaceuticals

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEC
Company Contact
Address: 1801 Maple Ave Ste 4300
EVANSTON IL 60201-3149
Tel: N/A
Website: https://www.aptinyx.com
IR: See website
Key People
Wilbur H. Gantz
Independent Chairman of the Board
Norbert G. Riedel
President, Chief Executive Officer, Director
Ashish Khanna
Chief Financial Officer, Chief Business Officer
Andrew Kidd
Chief Operating Officer
Joseph R. Moskal
Chief Scientific Officer
Business Overview
Aptinyx Inc. is a clinical-stage biopharmaceutical company. The Company discovers and develops therapies for disorders of the brain and nervous system. The Company has a platform for discovering compounds that work through a mechanism, which includes modulation of the N-methyl-D-aspartate (NMDA) receptor to develop pathways involved with nerve cell communication. The Company's compounds are effective on disease models including, depression, neuropathic pain, migraine, traumatic brain injury and age-induced learning impairment. The Company's compounds facilitate receptor activation without over-activating the receptor. The Company's lead product candidate is NYX-2925, a treatment for the painful diabetic peripheral neuropathy. It is also developing NYX-783 for the treatment of post-traumatic stress disorder and NYX-458 for Parkinson's disease cognitive impairment. The Company in partnership with Allergan plc, develops AGN-241751 for major depressive disorder indications.
Financial Overview
For the nine months ended 30 September 2019, Aptinyx Inc revenues decreased 50% to $2.8M. Net loss increased 11% to $43.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Stock-based Compensation in SGA increase from $1.4M to $4.8M (expense), General and administrative increase of 49% to $9.6M (expense).
Employees: 63 as of Mar 18, 2019
Reporting Currency: U.S. Dollars
Enterprise value: N/A
Annual revenue (TTM): $3.79M as of Dec 31, 2019
EBITDA (TTM): -$59.64M as of Dec 31, 2019
Net annual income (TTM): -$57.73M as of Dec 31, 2019
Free cash flow (TTM): -$51.67M as of Dec 31, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 45,371,631 as of Jan 10, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization